REFERENCES
2. Luger K, Dechassa ML, Tremethick DJ. New insights into nucleosome and chromatin structure: an ordered state or a disordered affair? Nat Rev Mol Cell Biol 2012;13:436-47.
3. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O’Dwyer PJ, et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 2010;28:2839-46.
4. Wong SHM, Kong WY, Fang CM, Loh HS, Chuah LH, et al. The TRAIL to cancer therapy: Hindrances and potential solutions. Crit Rev Oncol Hematol 2019;143:81-94.
5. Fulton MD, Brown T, Zheng YG. Mechanisms and Inhibitors of Histone Arginine Methylation. Chem Rec 2018;18:1792-807.
7. Song S, Yu Y. Progression on citrullination of proteins in gastrointestinal cancers. Front Oncol 2019;9:1-6.
8. Hyun K, Jeon J, Park K, Kim J. Writing, erasing and reading histone lysine methylations. Exp Mol Med 2017;49.
9. Sanaei M, Kavoosi F. Histone deacetylases and histone deacetylase inhibitors: molecular mechanisms of action in various cancers. Adv Biomed Res 2019;8:63.
10. Audia JE, Campbell RM. Histone modifications and cancer. Cold Spring Harb Perspect Biol 2016;8:a019521.
11. Kebede AF, Nieborak A, Shahidian LZ, Le Gras S, Richter F, et al. Histone propionylation is a mark of active chromatin. Nat Struct Mol Biol 2017;24:1048-56.
12. Goudarzi A, Zhang D, Huang H, Barral S, Kwon OK, et al. Dynamic Competing Histone H4 K5K8 Acetylation and Butyrylation Are Hallmarks of Highly Active Gene Promoters. Mol Cell 2016;62:169-80.
13. Dai L, Peng C, Montellier E, Lu Z, Chen Y, et al. Lysine 2-hydroxyisobutyrylation is a widely distributed active histone mark. Nat Chem Biol 2014;10:365-70.
14. Ishiguro T, Tanabe K, Kobayashi Y, Mizumoto S, Kanai M, et al. Malonylation of histone H2A at lysine 119 inhibits Bub1-dependent H2A phosphorylation and chromosomal localization of shugoshin proteins. Sci Rep 2018;8:1-10.
15. Wang Y, Guo YR, Liu K, Yin Z, Liu R, et al. KAT2A coupled with the α-KGDH complex acts as a histone H3 succinyltransferase. Nature 2017;552:273-7.
16. Tan M, Luo H, Lee S, Jin F, Yang JS, et al. Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell 2011;146:1016-28.
17. Iberg AN, Espejo A, Cheng D, Kim D, Michaud-Levesque J, et al. Arginine methylation of the histone H3 tail impedes effector binding. J Biol Chem 2008;283:3006-10.
18. Zhao Q, Rank G, Tan YT, Li H, Moritz RL, et al. PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing. Nat Struct Mol Biol 2009;16:304-11.
19. Chang B, Chen Y, Zhao Y, Bruick RK. JMJD6 is a histone arginine demethylase. Science 2007;318:444-7.
20. Webby CJ, Wolf A, Gromak N, Dreger M, Kramer H, et al. JMJD6 catalyses lysyl-hydroxylation of U2AF65, a protein associated with RNA splicing. Science 2009;325:90-3.
21. Hong X, Zang J, White J, Wang C, Pan CH, et al. Interaction of JMJD6 with single-stranded RNA. Proc Natl Acad Sci U S A 2010;107:14568-72.
22. Mantri M, Krojer T, Bagg EA, Webby CJ, Butler DS, et al. Crystal structure of the 2-Oxoglutarate- and Fe(II)-dependent lysyl hydroxylase JMJD6. J Mol Biol 2010;401:211-22.
23. Li S, Ali S, Duan X, Liu S, Du J, et al. JMJD1B demethylates H4R3me2s and H3K9me2 to facilitate gene expression for development of hematopoietic stem and progenitor cells. Cell Rep 2018;23:389-403.
24. Hamam HJ, Palaniyar N. Post-translational modifications in netosis and nets-mediated diseases. Biomolecules 2019;9:1-25.
25. Kerimoglu C, Sakib MS, Jain G, Benito E, Burkhardt S, et al. KMT2A and KMT2B mediate memory function by affecting distinct genomic regions. Cell Rep 2017;20:538-48.
26. Shi YG, Tsukada Y. The discovery of histone demethylases. Cold Spring Harb Perspect Biol 2013;5:2-4.
27. Chen Y, Sprung R, Tang Y, Ball H, Sangras B, et al. Lysine propionylation and butyrylation are novel post-translational modifications in histones. Mol Cell Proteomics 2007;6:812-9.
28. Xie Z, Dai J, Dai L, Tan M, Cheng Z, et al. Lysine succinylation and lysine malonylation in histones. Mol Cell Proteomics 2012;11:100-7.
29. Jeusset L, McManus K. Developing targeted therapies that exploit aberrant histone ubiquitination in cancer. Cells 2019;8:165.
30. Cubeñas-Potts C, Matunis MJ. SUMO: a multifaceted modifier of chromatin structure and function. Dev Cell 2013;24:1-12.
32. Yang Y, Bedford MT. Protein arginine methyltransferases and cancer. Nat Rev Cancer 2012;13:37-50.
33. Pal S, Baiocchi RA, Byrd JC, Grever MR, Jacob ST, et al. Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma. EMBO J 2007;26:3558-69.
34. Chung J, Karkhanis V, Tae S, Yan F, Smith P, et al. Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) Silencing. J Biol Chem 2013;288:35534-47.
35. Zhu F, Guo H, Bates PD, Zhang S, Zhang H, et al. PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells. Leukemia 2019;33:2898-911.
36. Chung J, Karkhanis V, Baiocchi RA, Sif S. Protein arginine methyltransferase 5 (PRMT5) promotes survival of lymphoma cells via activation of WNT/β-catenin and AKT/GSK3β proliferative signaling. J Biol Chem 2019;294:7692-710.
37. Alinari L, Mahasenan KV, Yan F, Karkhanis V, Chung JH, et al. Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation. Blood 2015;125:2530-43.
38. Kim YR, Lee BK, Park RY, Nguyen NTX, Bae JA, et al. Differential CARM1 expression in prostate and colorectal cancers. BMC Cancer 2010;10:1-13.
39. Takahashi Y, Iwai M, Kawai T, Arakawa A, Ito T, et al. Aberrant expression of tumor suppressors CADM1 and 4.1B in invasive lesions of primary breast cancer. Breast Cancer 2012;19:242-52.
40. Zhong J, Cao RX, Zu XY, Hong T, Yang J, et al. Identification and characterization of novel spliced variants of PRMT2 in breast carcinoma. FEBS J 2012;279:316-35.
41. Yoshimatsu M, Toyokawa G, Hayami S, Unoki M, Tsunoda T, et al. Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. Int J Cancer 2011;128:562-73.
42. Cheung N, Chan LC, Thompson A, Cleary ML, So CWE. Protein arginine-methyltransferase-dependent oncogenesis. Nat Cell Biol 2007;9:1208-15.
43. Fedoriw A, Rajapurkar SR, O’Brien S, Gerhart SV, Mitchell LH, et al. Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss. Cancer Cell 2019;36:100-14.e25.
44. Stein EM, Garcia-Manero G, Rizzieri DA, Tibes R, Berdeja JG, et al. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood 2018;131:2662-9.
45. Waters NJ, Daigle SR, Rehlaender BN, Basavapathruni A, Campbell CT, et al. Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic target. J Control Release 2015;220:758-65.
46. Waters NJ. Preclinical pharmacokinetics and pharmacodynamics of pinometostat (EPZ-5676), a first-in-class, small molecule S-adenosyl methionine competitive inhibitor of DOT1L. Eur J Drug Metab Pharmacokinet 2017;42:891-901.
47. Campbell CT, Haladyna JN, Drubin DA, Thomson TM, Maria MJ, et al. Mechanisms of pinometostat (EPZ-5676) treatment-emergent resistance in MLL-rearranged leukemia. Mol. Cancer Ther 2017;16:1669-79.
48. Blum KA, Abramson J, Maris M, Flinn I, Goy A, et al. 41OA phase I study of CPI-0610, a bromodomain and extra terminal protein (BET) inhibitor in patients with relapsed or refractory lymphoma. Ann Oncol 2018;29:2018.
49. Wu T, Millar H, Gaffney D, Beke L, Mannens G, et al. JNJ-64619178, a selective and pseudo-irreversible PRMT5 inhibitor with potent in vitro and in vivo activity, demonstrated in several lung cancer models. Available from: https://cancerres.aacrjournals.org/content/78/13_Supplement/4859. [Last accessed on 17 Sep 2020].
50. Italiano A, Soria JC, Toulmonde M, Michot JM, Lucchesi C, et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol 2018;19:649-59.
51. Knutson SK, Kawano S, Minoshima Y, Warholic NM, Huang KC, et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther 2014;13:842-54.
52. Brach D, Johnston-Blackwell D, Drew A, Lingaraj T, Motwani V, et al. EZH2 inhibition by tazemetostat results in altered dependency on B-cell activation signaling in DLBCL. Mol Cancer Ther 2017;16:2586-97.
53. Kurmasheva RT, Sammons M, Favours E, Wu J, Kurmashev D, et al. Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2017;64.
54. Bauer TM, Besse B, Martinez-Marti A, Trigo JM, Moreno V, et al. Phase I, open-label, dose-escalation study of the safety, pharmacokinetics, pharmacodynamics, and efficacy of GSK2879552 in relapsed/refractory SCLC. J Thorac Oncol 2019;14:1828-38.
55. Mohammad HP, Smitheman KN, Kamat CD, Soong D, Federowicz KE, et al. A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC. Cancer Cell 2015;28:57-69.
56. Rasco D, Tolcher A, Siu LL, Heinhuis K, Postel-Vinay S, et al. A phase I, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of GSK3326595 in subjects with solid tumors and non-Hodgkin’s lymphoma. Available from: https://cancerres.aacrjournals.org/content/77/13_Supplement/CT038. [Last accessed on 17 Sep 2020].
57. Siu LL, Rasco DW, Vinay SP, Romano PM, J Menis FLO, et al. A phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumors. nn Oncol 2019;30:159.
58. Gerhart S V., Kellner WA, Thompson C, Pappalardi MB, Zhang XP, et al. Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing. Sci Rep 2018;8:1-15.
59. Husmann D, Gozani O. Histone lysine methyltransferases in biology and disease. Nat Struc. Mol Biol 2019;26:880-9.
60. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov 2012;11:384-400.
61. Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D. Histone methyltransferase activity of Zeste protein complex containing the Enhancer associated with a human multiprotein. Genes Dev 2002;16:2893-905.
62. Li B, Chng WJ. EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications. J Hematol Oncol 2019;12:118.
63. Lue JK, Amengual JE. Emerging EZH2 Inhibitors and Their Application in Lymphoma. Curr Hematol Malig Rep 2018;13:369-82.
64. McCabe MT, Graves AP, Ganji G, Diaz E, Halsey WS, et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci U S A 2012;109:2989-94.
65. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007;12:1247-52.
66. Lee HZ, Kwitkowski VE, Del Valle PL, Ricci MS, Saber H, et al. FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Clin Cancer Res 2015;21:2666-70.
67. Raedler LA. Farydak (Panobinostat): first HDAC inhibitor approved for patients with relapsed multiple myeloma. Am Heal drug benefits 2016;9:84-7.
68. Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012;119:2579-89.
69. Cosenza M, Civallero M, Marcheselli L, Sacchi S, Pozzi S. Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine. Apoptosis 2017;22:827-40.
70. Vogl DT, Raje N, Jagannath S, Richardson P, Hari P, et al. Ricolinostat, the first selective histone deacetylase 6 inhibitor, in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. Clin Cancer Res 2017;23:3307-15.
71. Minami J, Suzuki R, Mazitschek R, Gorgun G, Ghosh B, et al. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia 2014;28:680-9.
72. Tang S, Cheng B, Zhe N, Ma D, Xu J, et al. Histone deacetylase inhibitor BG45-mediated HO-1 expression induces apoptosis of multiple myeloma cells by the JAK2/STAT3 pathway. Anticancer Drugs 2018;29:61-74.
73. Harada T, Ohguchi H, Grondin Y, Kikuchi S, Sagawa M, et al. HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications. Leukemia 2017;31:2670-7.
74. Guerriero JL, Sotayo A, Ponichtera HE, Castrillon JA, Pourzia AL, et al. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. Nature 2017;543:428-32.
75. Marek L, Hamacher A, Hansen FK, Kuna K, Gohlke H, et al. Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells. J Med Chem 2013;56:427-36.
76. Li X, Guo Y, Kuang X, Zhao L, Li H, et al. Histone deacetylase inhibitor LMK-235-mediated HO-1 expression induces apoptosis in multiple myeloma cells via the JNK/AP-1 signaling pathway. Life Sci 2019;223:146-57.
77. Wanek J, Gaisberger M, Beyreis M, Mayr C, Helm K, et al. Pharmacological inhibition of class IIA HDACs by LMK-235 in pancreatic neuroendocrine tumor cells. Int J Mol Sci 2018;19:3128.
78. Gradilone SA, Radtke BN, Bogert PS, Huang BQ, Gajdos GB, et al. HDAC6 inhibition restores ciliary expression and decreases tumor growth. Cancer Res 2013;73:2259-70.
79. Woan KV, Lienlaf M, Perez-Villaroel P, Lee C, Cheng F, et al. Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: enhanced antitumor immunity and impaired cell proliferation. Mol Oncol 2015;9:1447-57.
80. Wang F, Zheng L, Yi Y, Yang Z, Qiu Q, et al. SKLB-23bb, A HDAC6-Selective inhibitor, exhibits superior and broad-spectrum antitumor activity via additionally targeting microtubules. Mol Cancer Ther 2018;17:763-75.
81. Ma XJ, Xu G, Li ZJ, Chen F, Wu D, et al. HDAC-selective inhibitor cay10603 has single anti-tumour effect in Burkitt’s lymphoma cells by impeding the cell cycle. Curr Med Sci 2019;39:228-36.
82. Wang Z, Tang F, Hu P, Wang Y, Gong J, et al. HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma. Oncol Rep 2016;36:589-97.
83. Bergman JA, Woan K, Perez-Villarroel P, Villagra A, Sotomayor EM, et al. Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. J Med Chem 2012;55:9891-9.
84. Wu H, Yang K, Zhang Z, Leisten ED, Li Z, et al. Development of multifunctional histone deacetylase 6 degraders with potent antimyeloma activity. J Med Chem 2019;62:7042-57.
85. Sun X, Xie Y, Sun X, Yao Y, Li H, et al. The selective HDAC6 inhibitor nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma. Biosci Rep 2019;39:1-11.
86. Rettig I, Koeneke E, Trippel F, Mueller WC, Burhenne J, et al. Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation. Cell Death Dis 2015;6:1-14.
87. Balasubramanian S, Ramos J, Luo W, Sirisawad M, Verner E, et al. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 2008;22:1026-34.
88. Lopez G, Bill KLJ, Bid HK, Braggio D, Constantino D, et al. HDAC8, a potential therapeutic target for the treatment of malignant peripheral nerve sheath tumors (MPNST). PLoS One 2015;10:1-12.
89. Wang R, He Y, Robinson V, Yang Z, Hessler P, et al. Targeting lineage-specific MITF pathway in human melanoma cell lines by A-485, the selective small-molecule inhibitor of p300/CBP. Mol Cancer Ther 2018;17:2543-50.
90. Lasko LM, Jakob CG, Edalji RP, Qiu W, Montgomery D, et al. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. Nature 2017;550:128-32.
91. Bowers EM, Yan G, Mukherjee C, Orry A, Wang L, et al. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem Biol 2010;17:471-82.
92. Dahlin JL, Nelson KM, Strasser JM, Barsyte-Lovejoy D, Szewczyk MM, et al. Assay interference and off-target liabilities of reported histone acetyltransferase inhibitors. Nat Commun 2017;8:1-14.
93. Wang R, He Y, Robinson V, Yang Z, Hessler P, et al. Targeting Lineage-specific MITF pathway in human melanoma cell lines by A-485, the selective small-molecule inhibitor of p300/CBP. Mol Cancer Ther 2018;17:2543-50.
94. Filippakopoulos P, Picaud S, Mangos M, Keates T, Lambert JP, et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 2012;149:214-31.
95. Wai DCC, Szyszka TN, Campbell AE, Kwong C, Lorna EWW, et al. The BRD3 ET domain recognizes a short peptide motif through a mechanism that is conserved across chromatin remodelers and transcriptional regulators. J Biol Chem 2018;293:7160-75.
96. Cochran AG, Conery AR, Sims RJ. Bromodomains: a new target class for drug development. Nat Rev Drug Discov 2019;18:609-28.
97. Sahni JM, Keri RA. Targeting bromodomain and extraterminal proteins in breast cancer. Pharmacol Res 2018;129:156-76.
98. Bechter O, Schöffski P. Make your best BET: the emerging role of BET inhibitor treatment in malignant tumors. Pharmacol Ther 2020;208:107479.
99. Faivre EJ, McDaniel KF, Albert DH, Mantena SR, Plotnik JP, et al. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer. Nature 2020;578:306-10.
100. Chen D, Lu T, Yan Z, Lu W, Zhou F, et al. Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins. Eur J Med Chem 2019;182:111633.
101. Rathore R, McCallum JE, Varghese E, Florea AM, Büsselberg D. Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs). Apoptosis 2017;22:898-919.
102. Von Karstedt S, Montinaro A, Walczak H. Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy. Nat Rev Cancer 2017;17:352-66.
103. Croft M, Siegel RM. Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases. Nat Rev Rheumatol 2017;13:217-33.
104. Liu X, Yue P, Khuri FR, Sun SY. Decoy receptor 2 (<em>DcR2</em>) is a p53 target gene and regulates chemosensitivity. Cancer Res 2005;65:9169-75.
105. Mansour NM, Bernal GM, Wu L, Crawley CD, Cahill KE, et al. Decoy receptor DcR1 is induced in a p50/Bcl3-dependent manner and attenuates the efficacy of temozolomide. Cancer Res 2015;75:2039-48.
106. Liu X, Yue P, Khuri FR, Sun SY. p53 upregulates death receptor 4 expression through an intronic p53 Binding site. Cancer Res 2004;64:5078-83.
107. Shetty S, Graham BA, Brown JG, Hu X, Vegh-Yarema N, et al. Transcription factor NF-κB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol Cell Biol 2005;25:5404-16.
108. Woo SM, Seo SU, Min KJ, Kwon TK. BIX-01294 sensitizes renal cancer Caki cells to TRAIL-induced apoptosis through downregulation of survivin expression and upregulation of DR5 expression. Cell Death Discov 2018;4:29.
109. Kim SY, Hong MN, Heo SH, Park S, Kwon TK, et al. Inhibition of euchromatin histone-lysine N-methyltransferase 2 sensitizes breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through reactive oxygen species-mediated activating transcription factor 4-C/EBP homologous protein-de. Mol Carcinog 2018;57:1492-506.
110. Benoit YD, Laursen KB, Witherspoon MS, Lipkin SM, Gudas LJ. Inhibition of PRC2 histone methyltransferase activity increases TRAIL-mediated apoptosis sensitivity in human colon cancer cells. J Cell Physiol 2013;228:764-72.
111. Kasman L, Onicescu G, Voelkel-Johnson C. Histone deacetylase inhibitors restore cell surface expression of the coxsackie adenovirus receptor and enhance CMV promoter activity in castration-resistant prostate cancer cells. Prostate Cancer 2012;2012:137163.
112. Srivastava RK, Kurzrock R, Shankar S. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo. Mol Cancer Ther 2010;9:3254-66.
113. Borbone E, Berlingieri MT, De Bellis F, Nebbioso A, Chiappetta G, et al. Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. Oncogene 2010;29:105-16.
114. Nebbioso A, Carafa V, Conte M, Tambaro FP, Ciro A, et al. C-Myc modulation and acetylation is a key HDAC inhibitor target in cancer. Clin Cancer Res 2017;23:2542-55.
115. Zhang B, Liu B, Chen D, Setroikromo R, Haisma HJ, et al. Histone deacetylase inhibitors sensitize TRAIL-induced apoptosis in colon cancer cells. Cancers (Basel) 2019;11:645.
116. Kurt IC, Sur I, Kaya E, Cingoz A, Kazancioglu S, et al. KDM2B, an H3K36-specific demethylase, regulates apoptotic response of GBM cells to TRAIL. Cell Death Dis 2017;8:e2897.
117. Tanaka H, Hoshikawa Y, Oh-hara T, Koike S, Naito M, et al. PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-κB activation. Mol Cancer Res 2009;7:557-69.
118. Li M, An W, Xu L, Lin Y, Su L, et al. The arginine methyltransferase PRMT5 and PRMT1 distinctly regulate the degradation of anti-apoptotic protein CFLAR L in human lung cancer cells. J Exp Clin Cancer Res 2019;38:1-13.
119. Kauh J, Fan S, Xia M, Yue P, Yang L, et al. C-FLIP degradation mediates sensitization of pancreatic cancer cells to trail-induced apoptosis by the histone deacetylase inhibitor LBH589. PLoS One 2010;5:e10376.
120. Symanowski J, Vogelzang N, Zawel L, Atadja P, Pass H, et al. A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL. J Thorac Oncol 2009;4:149-60.
121. Kerr E, Holohan C, McLaughlin KM, Majkut J, Dolan S, et al. Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis. Cell Death Differ 2012;19:1317-27.
122. Klingbeil O, Lesche R, Gelato KA, Haendler B, Lejeune P. Inhibition of bet bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents. Cell Death Dis 2016;7:1-13.
